September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Comparison the effectiveness of Ozurdex® and combined therapy of intravitreal bevacizumab and subtenon triamcinolone injection in recurred branch retinal vein occlusion with macular edema.
Author Affiliations & Notes
  • Sung Pyo Park
    KangDong Sacred Heart Hospital, Seoul,
  • Won Sup Lee
    KangDong Sacred Heart Hospital, Seoul,
  • Jin Young Kim
    Jeju National University, Jeju, Korea (the Republic of)
  • Yong Kyu Kim
    KangDong Sacred Heart Hospital, Seoul,
  • Footnotes
    Commercial Relationships   Sung Pyo Park, None; Won Sup Lee, None; Jin Young Kim, None; Yong Kyu Kim, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 5330. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sung Pyo Park, Won Sup Lee, Jin Young Kim, Yong Kyu Kim; Comparison the effectiveness of Ozurdex® and combined therapy of intravitreal bevacizumab and subtenon triamcinolone injection in recurred branch retinal vein occlusion with macular edema.. Invest. Ophthalmol. Vis. Sci. 2016;57(12):5330.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Intravitreal dexamethasone implant (Ozurdex®) or combined intravitreal bevacizumab and subtenon triamcinolone injection were used to subside macular edema(ME) in patients with branch retinal vein occlusion(BRVO).
We performed a prospective clinical study that we wanted to know the differences of between Ozurdex® and combined therapy at the efficacy to subside ME and effect to the IOP in patients with recurred BRVO.

Methods : The 22 participants visited in Kangdong sacred heart hospital, from 2013 to 2015 due to BRVO.
Inclusion criteria were BCVA < 0.4, central macular thickness(CMT) > 300 um in Optical coherence tomography(OCT), previous one time intravitreal Ozurdex® injection history due to BRVO with ME, recurred BRVO with ME. Exclusion criteria were retinal disease except BRVO, steroid responder, IOP > 20mmHg at the baseline. We performed ophthalmic examinations of visual acuity, BCVA, IOP (Goldmann applanation tonometer), fundus photography, autofluorescence photography, OCT (Time domain and spectralis) at the baseline and 1, 2, 3 months after injections. The relationship between initial and follow-up examination was analyzed using Paired t-test SPSS 18.0 (SPSS inc., Chicago, Illinos, USA) and P value of < 0.05.

Results : Average BCVA was 0.33 at baseline, 0.58 at 3 months after injection (p-value 0.01) in Ozurdex® group, 0.27 at baseline, 0.47 at 3 months (p-value 0.03) in combined therapy group.
Average IOP was 13.55mmHg at baseline,15.09 at 3 months (p-value 0.1) in Ozurdex® group, 13.45 at baseline, 13.18 at 3 months (p-value 0.75) in combined therapy group.
Average CMT was 578.6 um at baseline, 366.9 um at 3 months (p-value 0.002) in Ozurdex® group, 575.6 um at baseline, 397.2 um at 3 months (p-value 0.001) in combined therapy group.
Differences between baseline and 3 months after injection were as followed. (figure)

Conclusions : The central macular thickness and BCVA in both groups were turned out statistically improved during 3 months after injection. But the differences of BCVA, IOP, CMT between baseline and 3 months after injection in both groups were not statistically significant. Both dexamethasone implant and combined therapy can be effective options to subside macular edema in recurred branch retinal vein occlusion.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

 

Differences between baseline and 3 months after injection.

Differences between baseline and 3 months after injection.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×